RecruitingPhase 4NCT06116526

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Dupilumab De-escalation in Pediatric Atopic Dermatitis: A Pilot Trial

Sponsor

Johns Hopkins University

Enrollment

30 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

Eligibility

Min Age: 1 YearMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dupilumab - Discontinuation, a drug called Dupilumab - Dose Reduction, and others for people with atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.